Clinical Trials Directory

Trials / Completed

CompletedNCT01213498

The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Erling Bjerregaard Pedersen · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood. Nitric oxide (NO) production is reduced in several chronic diseases such as nephropathy, diabetes and hypertension. The purpose of this study is to investigate the effect of Atorvastatin treatment on the NO-system measuring renal and cardiovascular variables in patients witk chronic kidney disease.

Detailed description

Subjects will be examined on two examination days. 4 days prior to each examination day subjects are treated with either atorvastatin or placebo. During treatment periods subject are given a standardized diet. On the examination days subject are given L-NMMA(L-NG-monomethyl Arginine citrate), a NO inhibitor, 6 mg bolus infusion followed by continuous 4 mg/kg/hr infusion for 1 hour. Renal function, central hemodynamic and vasoactive hormones are evaluated prior, during and after L-NMMA infusion. Renal function is measured by renal clearance of 51Chromium-EDTA and urinary sodium, potassium and albumin concentration. Urinary excretion of protein from NCC, NKCC and ENaC will be measured to evaluate channel activity in the nephron. Central blood pressure, pulse wave analysis, and augmentation index are measured using SphygmoCor® from Atcor.

Conditions

Interventions

TypeNameDescription
DRUGAtorvastatinZarator, 80 mg pr. day for 5 days
DRUGUnikalk1 tablet Unikalk pr day for 5. days

Timeline

Start date
2010-05-01
Primary completion
2012-01-01
Completion
2012-01-01
First posted
2010-10-04
Last updated
2015-08-21

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01213498. Inclusion in this directory is not an endorsement.